GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway-Reference-Cited by-同舟云学术

GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway

Published:2024-08-03 Issue: Volume: Page:
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Ikeuchi Hiroshi,Matsuno Yusuke,Kusumoto-Matsuo Rika,Kojima Shinya,Ueno Toshihide^ORCID,Ikegami Masachika,Kitada Rina,Sumiyoshi-Okuma Hitomi,Kojima Yuki,Yonemori Kan^ORCID,Yatabe Yasushi^ORCID,Takamochi Kazuya,Suzuki Kenji,Yoshioka Ken-ichi,Mano Hiroyuki^ORCID,Kohsaka Shinji^ORCID

Funder

Japan Agency for Medical Research and Development

MEXT | Japan Society for the Promotion of Science

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41388-024-03105-1.pdf

Reference53 articles.

1. Kohsaka S, Nagano M, Ueno T, Suehara Y, Hayashi T, Shimada N. et al. A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer. Sci Transl Med. 2017;9:eaan6566.

2. Ikeuchi H, Hirose T, Ikegami M, Takamochi K, Suzuki K, Mano H, et al. Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model. Oncogene. 2022;41:2470–9.

3. Hayes TK, Aquilanti E, Persky NS, Yang X, Kim EE, Brenan L, et al. Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants. Nat Commun. 2024;15:2742.

4. Robichaux JP, Le X, Vijayan RSK, Hicks JK, Heeke S, Elamin YY, et al. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature. 2021;597:732–7.

5. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–9.